Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 44

1.

Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma.

Patnaik A, Weiss GJ, Papadopoulos KP, Hofmeister CC, Tibes R, Tolcher A, Isaacs R, Jac J, Han M, Payumo FC, Cotreau MM, Ramanathan RK.

Br J Cancer. 2014 Jul 15;111(2):272-80. doi: 10.1038/bjc.2014.290. Epub 2014 Jun 5.

PMID:
24901237
[PubMed - in process]
2.

Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms.

Mughal TI, Vannucchi AM, Soverini S, Bazeos A, Tibes R, Saglio G, Abdel-Wahab O, Pardanani A, Hehlmann R, Barbui T, Van Etten R, Tefferi A, Goldman JM.

Haematologica. 2014 May;99(5):797-801. doi: 10.3324/haematol.2013.097832. No abstract available.

PMID:
24790057
[PubMed - in process]
Free PMC Article
3.

Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies.

Bogenberger JM, Delman D, Hansen N, Valdez R, Fauble V, Mesa RA, Tibes R.

Leuk Lymphoma. 2014 Jun 17:1-4. [Epub ahead of print] No abstract available.

PMID:
24707940
[PubMed - as supplied by publisher]
4.

Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies.

Tibes R, Mesa RA.

J Hematol Oncol. 2014 Mar 5;7:18. doi: 10.1186/1756-8722-7-18.

PMID:
24598114
[PubMed - in process]
Free PMC Article
5.

Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents.

Carter BZ, Mak PY, Mak DH, Shi Y, Qiu Y, Bogenberger JM, Mu H, Tibes R, Yao H, Coombes KR, Jacamo RO, McQueen T, Kornblau SM, Andreeff M.

J Natl Cancer Inst. 2014 Feb;106(2):djt440. doi: 10.1093/jnci/djt440.

PMID:
24526787
[PubMed - indexed for MEDLINE]
6.

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.

Bogenberger JM, Kornblau SM, Pierceall WE, Lena R, Chow D, Shi CX, Mantei J, Ahmann G, Gonzales IM, Choudhary A, Valdez R, Camoriano J, Fauble V, Tiedemann RE, Qiu YH, Coombes KR, Cardone M, Braggio E, Yin H, Azorsa DO, Mesa RA, Stewart AK, Tibes R.

Leukemia. 2014 Aug;28(8):1657-65. doi: 10.1038/leu.2014.44. Epub 2014 Jan 23.

PMID:
24451410
[PubMed - in process]
Free PMC Article
7.

CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.

Chaudhuri L, Vincelette ND, Koh BD, Naylor RM, Flatten KS, Peterson KL, McNally A, Gojo I, Karp JE, Mesa RA, Sproat LO, Bogenberger JM, Kaufmann SH, Tibes R.

Haematologica. 2014 Apr;99(4):688-96. doi: 10.3324/haematol.2013.093187. Epub 2013 Oct 31.

PMID:
24179152
[PubMed - in process]
Free PMC Article
8.

Emerging drugs for polycythemia vera.

Tibes R, Mesa RA.

Expert Opin Emerg Drugs. 2013 Sep;18(3):393-404. doi: 10.1517/14728214.2013.832754. Review.

PMID:
23968379
[PubMed - indexed for MEDLINE]
9.

Ruxolitinib in clinical practice for therapy of myelofibrosis: single USA center experience following Food and Drug Administration approval.

Geyer H, Cannon K, Knight E, Fauble V, Camoriano J, Emanuel R, Tibes R, Mesa R.

Leuk Lymphoma. 2014 Jan;55(1):195-7. doi: 10.3109/10428194.2013.789507. Epub 2013 Jun 12. No abstract available.

PMID:
23647081
[PubMed - indexed for MEDLINE]
10.

Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors.

Jimeno A, Weiss GJ, Miller WH Jr, Gettinger S, Eigl BJ, Chang AL, Dunbar J, Devens S, Faia K, Skliris G, Kutok J, Lewis KD, Tibes R, Sharfman WH, Ross RW, Rudin CM.

Clin Cancer Res. 2013 May 15;19(10):2766-74. doi: 10.1158/1078-0432.CCR-12-3654. Epub 2013 Apr 10.

PMID:
23575478
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

18-FDG PET/CT assessment of basal cell carcinoma with vismodegib.

Thacker CA, Weiss GJ, Tibes R, Blaydorn L, Downhour M, White E, Baldwin J, Hoff DD, Korn RL.

Cancer Med. 2012 Oct;1(2):230-6. doi: 10.1002/cam4.33. Epub 2012 Sep 17.

PMID:
23342272
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Effect of selection of QTc formula on eligibility of cancer patients for phase I clinical trials.

Borad MJ, Soman AD, Benjamin M, Casa D, Tembe WD, Piper BF, Ramanathan R, Tibes R, Jameson G, Ansaldo K, Von Hoff DD.

Invest New Drugs. 2013 Aug;31(4):1056-65. doi: 10.1007/s10637-012-9909-4. Epub 2012 Dec 16.

PMID:
23242862
[PubMed - indexed for MEDLINE]
13.

JAK inhibition: the key to treating myeloproliferative neoplasm?

Tibes R, Bogenberger JM, Mesa RA.

Expert Rev Hematol. 2012 Dec;5(6):583-5. doi: 10.1586/ehm.12.55. No abstract available.

PMID:
23216589
[PubMed - indexed for MEDLINE]
14.

A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors.

Tibes R, Fine G, Choy G, Redkar S, Taverna P, Oganesian A, Sahai A, Azab M, Tolcher AW.

Cancer Chemother Pharmacol. 2013 Feb;71(2):463-71. doi: 10.1007/s00280-012-2019-3. Epub 2012 Nov 23.

PMID:
23178951
[PubMed - indexed for MEDLINE]
15.

A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors.

Jameson GS, Hamm JT, Weiss GJ, Alemany C, Anthony S, Basche M, Ramanathan RK, Borad MJ, Tibes R, Cohn A, Hinshaw I, Jotte R, Rosen LS, Hoch U, Eldon MA, Medve R, Schroeder K, White E, Von Hoff DD.

Clin Cancer Res. 2013 Jan 1;19(1):268-78. doi: 10.1158/1078-0432.CCR-12-1201. Epub 2012 Nov 7.

PMID:
23136196
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Phase I trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphoma.

Mahadevan D, Northfelt DW, Chalasani P, Rensvold D, Kurtin S, Von Hoff DD, Borad MJ, Tibes R.

Int J Clin Oncol. 2013 Oct;18(5):934-41. doi: 10.1007/s10147-012-0475-8. Epub 2012 Oct 11.

PMID:
23053399
[PubMed - indexed for MEDLINE]
17.

Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.

Tibes R, Bogenberger JM, Benson KL, Mesa RA.

Mol Diagn Ther. 2012 Oct;16(5):269-83. doi: 10.1007/s40291-012-0006-3. Review.

PMID:
23023734
[PubMed - indexed for MEDLINE]
18.

MPN blast phase: clinical challenge and assessing response.

Mesa RA, Tibes R.

Leuk Res. 2012 Dec;36(12):1496-7. doi: 10.1016/j.leukres.2012.08.026. Epub 2012 Sep 19. No abstract available.

PMID:
22999527
[PubMed - indexed for MEDLINE]
19.

JAK2 inhibitors in the treatment of myeloproliferative neoplasms.

Tibes R, Bogenberger JM, Geyer HL, Mesa RA.

Expert Opin Investig Drugs. 2012 Dec;21(12):1755-74. doi: 10.1517/13543784.2012.721352. Epub 2012 Sep 19. Review.

PMID:
22991927
[PubMed - indexed for MEDLINE]
20.

The impact of concomitant medication use on patient eligibility for phase I cancer clinical trials.

Borad MJ, Curtis KK, Babiker HM, Benjamin M, Tibes R, Ramanathan RK, Wright K, Dueck AC, Jameson G, Von Hoff DD.

J Cancer. 2012;3:345-53. doi: 10.7150/jca.4714. Epub 2012 Aug 17.

PMID:
22962561
[PubMed]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk